Alpha Cognition Inc
ACOG
Get informed when a big investor buys or sells
+ FollowMarket Cap$140.4M
Close$
$4.30
50.3% downside
Current Fair Value
50.3% downsideOvervalued by 50.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $140.40 Million |
|---|---|
| Enterprise Value | $99.12 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.17 |
| Beta | 2.23 |
| Outstanding Shares | 21,774,104 |
Return
| Return on Equity | -44.26% |
|---|---|
| Return on Assets | -36.33% |
| Return on Invested Capital | -47.61% |
Valuation & Multiples
| P/E Ratio | -8.28 |
|---|---|
| PEG | 51.12 |
| Price to Sales | - |
| Price to Book Ratio | 4.33 |
| Enterprise Value to Revenue | 6.5 |
| Enterprise Value to EBIT | -3.58 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
$4.38 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$7.04 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 48.17%▼ 0.23% |
|---|---|
| Total Invested | $75.73M▲ 30.97% |
| Investors Holding | 26▲ 1.00% |
ESG Score
No data
About Alpha Cognition Inc
71 employees
CEO: Michael E. McFadden Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUN...